8-K: Firefly Neuroscience Secures $8M in Additional Funding

Firefly Neuroscience has completed an additional $8 million private placement, issuing 5.33 million units at $1.50 per unit.

Summary

• The company completed an additional closing under a previously announced Securities Purchase Agreement dated March 8, 2026.
• Issued 5,333,333 units to an accredited investor at a price of $1.50 per unit, totaling $8 million in gross proceeds.
• The transaction includes an Amended and Restated Lock-Up Agreement restricting the transfer of securities until May 16, 2026.
• The deadline for filing the required Registration Statement with the SEC has been extended to May 21, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while it provides necessary liquidity, the continued reliance on dilutive private placements highlights ongoing capital requirements.

Positives

• Successfully raised $8 million in additional capital to support operations.
• Maintained the same unit pricing of $1.50 as the initial March 2026 closing, indicating stable investor valuation.
• Secured an extension on the Registration Statement filing deadline, providing more operational flexibility.

Negatives

• Dilution of existing shareholders through the issuance of 5.33 million additional units.
• Continued reliance on private placements for capital, which may signal limited access to traditional credit markets.

Risks

• The company is subject to strict lock-up provisions until May 16, 2026, limiting liquidity for investors.
• Failure to meet the extended May 21, 2026, deadline for the Registration Statement could trigger further contractual complications.
• The securities issued are unregistered, limiting their immediate marketability and liquidity.

Future Outlook

The company is committed to filing a Registration Statement by May 21, 2026, and aims to have it become effective within 45 to 90 days depending on SEC review status.

Management Comments

• Management has executed the additional closing under the terms established in the March 2026 Securities Purchase Agreement.

Industry Context

StockSavvy.ai notes that small-cap biotech and neuroscience firms frequently utilize private placements with warrants to bridge funding gaps, though this often results in significant equity dilution and downward pressure on share prices in the short term.

Comparison to Industry Standards

• The use of private placements with lock-up agreements is standard practice for Nasdaq-listed micro-cap companies.
• The $1.50 unit price reflects the current market valuation for similar early-stage neuroscience technology firms.

Corporate Governance

Stakeholder Impact

• Shareholders face dilution due to the issuance of 5.33 million new units.
• Investors in the private placement are subject to lock-up restrictions until May 16, 2026.

Next Steps

• File the Registration Statement with the SEC by May 21, 2026.
• Monitor the expiration of the Lock-Up Period on May 16, 2026.

Key Dates

Recommendation

The company is successfully raising capital, but the reliance on dilutive private placements suggests a need for caution until the company demonstrates a path to self-sustaining revenue.

Keywords

Firefly Neuroscience, Private Placement, Capital Raise, AIFF, Securities Purchase Agreement, Lock-Up Agreement